Skip to main content
Premium Trial:

Request an Annual Quote

NIDA Plans $10M for Addiction Genomics Research

NEW YORK (GenomeWeb News) – The National Institute of Drug Abuse will give $10 million in 2010 to fund deep sequencing studies aimed at identifying SNP variants and structural variants that may affect addiction risk in samples that are known to have drug abuse phenotypes.

NIDA plans to issue up to four grants of as much as $2.5 million per year for five years for research that will explore particular pharmacogenomic regions already identified by genome-wide association studies and other means and which could benefit from deep next-generation sequencing and analysis.

The aim of the grant program is to support studies that will identify variants with rare to moderate frequencies that affect risk for addiction phenotypes. In addition to regions identified by GWAS, researchers may sequence candidate genes in individuals with extreme phenotypes, or other approaches that capitalize on genetic architecture.

The research may involve studies that will sequence replicated candidate regions associated with drug addiction; research into the genomic structure, including microdeletions and gene amplifications, across the human genome; integration of computational and experimental components, and comparative sequence analysis of candidate genes with model organisms; and identification of rare variants in genealogically defined populations using long-range phasing and haplotype imputation.

Applicants are encouraged to use the HapMap and 1000 Genomes projects, and they must use existing DNA samples that have been well characterized for addiction phenotypes.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more